Atlas Trials

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Clinical trial NCT05254847 · COMPLETED

Trial details

NCT number
NCT05254847
Sponsor
Fudan University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2022-02-24
Primary completion
2023-12-31
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.